Skip to content

Medical emergency? What to do

EU to take another look at GSK breast cancer drug

3-RXPublished March 19, 20082 min read

Key points

  • Europe's drugs regulators will take another look at GlaxoSmithKline Plc's new breast cancer pill Tyverb after new data showed a small risk of higher liver enzymes during treatment with the drug.
  • CHMP recommended conditional approval for Tyverb in December, meaning it could go on sale but that additional data were required.
  • "It's potentially a slight delay to the rubber-stamping of the official approval," he said.
  • Elevated liver enzymes generally returned to normal when the patients stopped taking Tyverb," it said in a statement.

Europe's drugs regulators will take another look at GlaxoSmithKline Plc's new breast cancer pill Tyverb after new data showed a small risk of higher liver enzymes during treatment with the drug.

GSK, Europe's biggest drug maker, said on Tuesday that the European Commission had referred Tyverb, which is on sale in the United States under the name Tykerb, back to the EU's Committee for Medicinal Products for Human Use (CHMP).

CHMP recommended conditional approval for Tyverb in December, meaning it could go on sale but that additional data were required.

GSK said it did not believe the new data changed the risk-benefit profile for Tyverb, and Nomura Code analyst Mike Ward agreed it was no more than a minor setback.

"It's potentially a slight delay to the rubber-stamping of the official approval," he said.

GSK said a review of clinical trial and post-marketing data showed that hepatotoxicity - predominately elevated liver enzymes - could occur during treatment with Tyverb, but that the overall incidence of this was only four in 1,000 patients.

"Severe hepatotoxicity has been uncommon. Elevated liver enzymes generally returned to normal when the patients stopped taking Tyverb," it said in a statement.

"GSK has informed investigators in ongoing clinical trials, and healthcare providers in those countries where Tyverb is approved, to recommend increased frequency of blood tests to monitor liver function."

GSK said it expected Tyverb would be discussed at the next meeting of the CHMP from April 21-24.

"It'll have to go on the label for sure...but in the context of people dying of cancer I don't think it's a major issue," Nomura Code's Ward said.

At 1500 GMT, GSK shares were up 2.4 percent at 1,039 pence, versus a 2 percent rise on the DJ Stoxx European healthcare index.

Tyverb is one of GSK's biggest new drug hopes, and the first of several cancer medicines that it hopes to have approved by 2010. Studies of the product are also underway to treat early-stage and inflammatory breast cancers, as well as head and neck, gastric and lung cancers.

Tyverb is designed to be given in combination with Roche's Xeloda for treating patients with advanced or metastatic breast cancer whose tumours overexpress the HER2 protein.

Because Tykerb, known generically as lapatinib, is given as a pill it is more convenient than Roche and Genentech Inc's blockbuster Herceptin, which works in a similar way but must be injected.

Unlike Herceptin, which aims to block cancer from outside the cell, Tykerb works within cells by blocking two enzymes thought to promote cancer.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Keep reading

Brain

Italy court ruling links mobile phone use to tumor

Italy's supreme court has upheld a ruling that said there was a link between a business executive's brain tumor and his heavy mobile phone usage, potentially opening the door to further legal claims. The court's…

2 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.